Trial Profile
A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Inarigivir soproxil (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 Mar 2022 Status changed from completed to discontinued.
- 26 Jun 2021 Results presented at The International Liver Congress 2021
- 20 Nov 2020 According to a F-star Therapeutics media release, F-star Therapeutics has acquired Spring Bank Pharmaceuticals. The Spring Bank has been re-named to F-star Therapeutics.